# T-MAXIMUM Pharmaceutical

Source: https://onco.cc/companies/t-maximum-pharmaceutical/  
OnCo record `t-maximum-pharmaceutical` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

T-MAXIMUM Pharmaceutical develops ready-made CAR-T cell therapies from healthy donors for solid tumours. Its lead, MT027, targets B7-H3 and is given into the fluid around the brain in trials for recurrent glioblastoma and brain metastases.

## Summary

T-MAXIMUM Pharmaceutical is a clinical-stage cell therapy company developing allogeneic CAR-T products for locoregionally accessible solid tumours, with research bases listed in Ningbo, Suzhou, Chongqing, Yantai, Hong Kong and the United States. Its lead, MT027, is an off-the-shelf, donor-derived CAR-T therapy targeting B7-H3; the company announced FDA IND clearance in December 2025 to proceed to a phase 2 trial in recurrent glioblastoma. Its registered phase 2 trials give MT027 by intracerebroventricular injection: GLIOMAX in recurrent glioma (NCT07386002) and METAMAX in brain metastases from advanced solid tumours (NCT07897799). Other pipeline programmes are MT029 (EGFR) and MT026 and MT028 (IL-13R alpha 2 and HER2) in solid tumours. Its first registered cancer trial, NCT07386002, was posted on ClinicalTrials.gov in February 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: T-MAXIMUM Pharmaceutical Inc; T-MAXIMUM
- HQ: Beijing
- Type: cell-therapy
- Website: https://t-maximum.com/

## Notes

- Headquarters not stated on the website; Beijing is the dateline of the December 2025 release, and the company lists research bases in Ningbo, Suzhou, Chongqing, Yantai, Hong Kong and the United States.
- Founding year and headquarters not stated on the website or the December 2025 release (datelined Beijing); country follows the Chinese research bases.
- The website links ASCO 2024 clinical progress, so MT027 was in human studies before its first ClinicalTrials.gov registration; earlier studies were not traced.
- No financing amounts or investors are named.
- Company website and December 2025 release read on 29 October 2026.

## Sources

- Official website: https://t-maximum.com/
- MT027 FDA IND clearance, December 2025: https://www.prnewswire.com/news-releases/t-maximum-pharmaceuticals-allogeneic-car-t-therapy-mt027-receives-fda-ind-clearance-to-proceed-to-phase-ii-clinical-trial-for-recurrent-glioblastoma-302647537.html
- ClinicalTrials.gov: GLIOMAX phase 2 trial of MT027 (NCT07386002): https://clinicaltrials.gov/study/NCT07386002
- ClinicalTrials.gov: METAMAX phase 2 trial of MT027 (NCT07897799): https://clinicaltrials.gov/study/NCT07897799

## Connected records

- cancers: [Brain metastases (secondary brain tumours)](https://onco.cc/cancers/secondary-brain-tumours/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)](https://onco.cc/technologies/glioma-car-t/)
- targets: [B7-H3](https://onco.cc/targets/b7h3/), [EGFR](https://onco.cc/targets/egfr/), [HER2](https://onco.cc/targets/her2/)

---
JSON: https://onco.cc/api/v1/entities/t-maximum-pharmaceutical.json